Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 venadaparib + paclitaxel + ramucirumab for HRR-deficient gastric cancer (second-line)
KCT0009067Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venadaparib in gastric cancer (GC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
venadaparib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0009067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009067.